NKTX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

KUPNO 113681 min ago

@ $10.55

Wydano: 14 vas. 2024 @ 17:41

Zwrot: -25.08%

Poprzedni sygnał: vas. 14 - 16:30

Poprzedni sygnał: Sprzedaż

Zwrot: -3.61 %

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 17:21):

Stats
Dzisiejszy wolumen	148 312
Średni wolumen	996 069
Kapitalizacja rynkowa	556.69M
EPS	$0 ( 2024-03-21 )
Następna data zysków	( $-0.560 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.29
ATR14	$0.0680 (0.86%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-27	Ra Capital Management, L.p.	Buy	3 000 000	Common Stock
2024-03-27	Ra Capital Management, L.p.	Buy	3 000 031	Pre- Funded Warrants (Right to Buy)
2024-03-27	George Simeon	Buy	1 548 341	Common Stock
2024-03-27	George Simeon	Buy	451 659	Common Stock
2024-03-01	Hastings Paul J	Sell	12 358	Common Stock

INSIDER POWER
95.73
Last 99 transactions
Buy: 11 537 422 \| Sell: 349 926

Wolumen Korelacja

Długi: -0.15 (neutral)

Krótki: 0.06 (neutral)

Signal:(32.157) Neutral

Nkarta, Inc. Korelacja

10 Najbardziej pozytywne korelacje
ANAB	0.894
REGN	0.878
PBBK	0.876
RFIL	0.876
GANX	0.873
FTXH	0.872
CFBK	0.871
CMPS	0.863
CSX	0.861
ARCT	0.861

10 Najbardziej negatywne korelacje
RMRM	-0.872
SEV	-0.861
SVOK	-0.86
AMTI	-0.855
MLVF	-0.844
RAAC	-0.844
HOLUU	-0.819
BFRI	-0.808
OSMT	-0.806
GHVI	-0.805

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Nkarta, Inc. Korelacja - Waluta/Towar

-0.69
( moderate negative )

-0.65
( moderate negative )

0.00
( neutral )

-0.60
( weak negative )

-0.40
( neutral )

-0.54
( weak negative )

Nkarta, Inc. Finanse

Annual	2023
Przychody:	$0
Zysk brutto:	$-5.87M (0.00 %)
EPS:	$-2.40

FY	2023
Przychody:	$0
Zysk brutto:	$-5.87M (0.00 %)
EPS:	$-2.40

FY	2022
Przychody:	$0
Zysk brutto:	$-6.57M (0.00 %)
EPS:	$-2.74

FY	2021
Przychody:	$0.00
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-2.62

Financial Reports:

No articles found.

Nkarta, Inc.

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.